Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | PIN4 | Q9Y237 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6848928 | 0.86 | TNF (0.49) | ALDH1A1KDM4ELMNA | |
| SCHEMBL5885705 | 0.84 | KDM4E (0.49) | ALDH1A1KDM4EGSK3AGSK3BCYP1A2 | |
| SCHEMBL7451716 | 0.81 | LMNA (0.41) | ALDH1A1KDM4ELMNA | |
| SCHEMBL14281098 | 0.81 | RAB9A (0.44) | ALDH1A1KDM4ERAB9AKMT2AGAA | |
| SCHEMBL7139116 | 0.79 | KDM4E (0.45) | ALDH1A1KDM4EGSK3AGSK3BCYP1A2 | |
| SCHEMBL29161288 | 0.74 | ALDH1A1 (0.50) | ALDH1A1KDM4EGSK3AGSK3BCYP1A2 | |
| SCHEMBL5856969 | 0.73 | FPR2 (0.50) | ALDH1A1KDM4EGSK3AGSK3BRAB9A | |
| SCHEMBL23014869 | 0.71 | ALDH1A1 (0.57) | ALDH1A1KDM4EGSK3AGSK3BCYP1A2 | |
| SCHEMBL23460858 | 0.71 | KDM4E (0.48) | ALDH1A1KDM4EGSK3AGSK3BCYP1A2 | |
| SCHEMBL12636632 | 0.71 | ALDH1A1 (0.48) | ALDH1A1KDM4EGSK3AGSK3BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| EP-3802489-A2 | MASP-2 INHIBITORS AND METHODS OF USE | Omeros Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20080021044-A1 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | PATEL MITUL N | 2008-01-24 | — | — | US | disclosed |
| US-20080021044-A1 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | PATEL MITUL N | 2008-01-24 | — | — | US | disclosed |
| US-20080021044-A1 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | PATEL MITUL N | 2008-01-24 | — | — | US | disclosed |
| WO-2007146553-A2 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146553-A2 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-12-21 | — | — | WO | disclosed |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| US-6462050-B1 | FOR TREATING OR PREVENTING VENOUS, CARDIOGENIC, AND ARTERIAL THROMBOSIS/EMBOLISM, ATHERSCLEROSIS, AND FOR LOWERING PROPENSITY OF DEVICES THAT COME INTO CONTACT WITH BLOOD TO CLOT BLOOD | MERCK & CO., INC. | 2002-10-08 | — | — | US | disclosed |
| US-6455532-B1 | ANTICOAGULANTS | MERCK & CO., INC. | 2002-09-24 | — | — | US | disclosed |
| US-20020052357-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1189899-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2002-03-27 | — | — | EP | disclosed |
| US-20020035115-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2002-03-21 | — | — | US | disclosed |
| WO-2002009711-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| US-20020006923-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001070229-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2000075134-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-12-14 | — | — | WO | disclosed |
| US-6011038-A | Pyrazinone thrombin inhibitors | MERCK & CO., INC. (US) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052357-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, SERPINE1, TFPI | ALDH1A1 2762/4885KDM4E 2813/4885GSK3A 1521/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ALDH1A1 4701/4885KDM4E 4128/4885GSK3A 4411/4885 |
| US-20020006923-A1 | Thrombin inhibitors | F2, F11, F12 | ALDH1A1 2957/4885KDM4E 1690/4885GSK3A 2455/4885 |
| US-20080021044-A1 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | DNPEP, SPINT2, PEPD | ALDH1A1 910/4885KDM4E 1557/4885GSK3A 3075/4885 |
| US-20020035115-A1 | Thrombin inhibitors | TFPI, PLAT, F2 | ALDH1A1 4534/4885KDM4E 2960/4885GSK3A 1540/4885 |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | F2, F12, SERPINC1 | ALDH1A1 716/4885KDM4E 1302/4885GSK3A 2042/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ALDH1A1 4701/4885KDM4E 4128/4885GSK3A 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.